Comparative effectiveness and pharmacological fingerprints of indobufen versus rivaroxaban in patients with chronic kidney disease: a single-center, real-world study
In this real-world CKD cohort, indobufen and rivaroxaban demonstrated comparable clinical effectiveness and safety. Combining machine learning with longitudinal models helps to statistically adjust for complex confounders like polypharmacy, thereby providing a more robust estimate of a drug's independent effect.
Authors
- Jiameng Tang (ORCID: https://orcid.org/0000-0002-6559-7720)
- Jun Ning (ORCID: https://orcid.org/0000-0003-2169-055X)
- Tingting Huang (ORCID: https://orcid.org/0000-0002-9747-7969)
- Chuanfu Huang (ORCID: https://orcid.org/0000-0002-4612-8224)
- Mingbo Liu (ORCID: https://orcid.org/0000-0002-0540-2573)
- Lijun Zhang (ORCID: https://orcid.org/0000-0002-9266-268X)
- He Zhang (ORCID: https://orcid.org/0009-0004-6985-7499)
- Chen Zhao (ORCID: https://orcid.org/0009-0005-2510-3174)
- Zhiren Pan
Institutions
- Beibu Gulf University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fphar.2025.1694163
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00